Cases & Deals

Celgene acquires Triphase Accelerator's first compound, Marizomib

Clients Celgene Corporation

Jones Day advised Celgene Corporation in the acquisition, through an affiliate, of Triphase Accelerator Corporation's assets related to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.

In addition to M&A representation, Jones Day provided health care, intellectual property, tax, and regulatory advice regarding this transaction.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.